Antihypertensive & Anti-diabetic Activity of Simvastatin & Reserpine in Ang-II Induced Hypertension and STZ Induced Type-II Diabetes Mellitus

Abstract

The aim of the present investigation is to study in-vivo anti-hypertensive activity of identified sEHIs using Angiotensin II induced hypertension and anti-diabetic activity. Male wistar rats (200-250 g) were obtained from Veterinary and Animal Sciences, India. The experiments were performed strictly according to guidelines provided by CPCSEA and approved by IAEC. In this study, osmotic mini- pumps (model 2002, Alzet, Cupertino, CA, USA) were implanted subcutaneously under anaesthesia (ketamine 80 mg/kg along with xylazine 10 mg/kg, intraperitoneally) for continuous administration of Ang II (150 ng/kg/min; n=6) for 2 weeks. The anti-diabetic effect of simvastatin and reserpine was investigated using earlier reported methods with slight modifications. Briefly, rats were randomly grouped in six groups. The acute toxicity study showed that oral administration of simvastatin and reserpine (2.5, 5, 10, 25, 50, 75, 100 mg/kg) caused dose dependent behavioral effects. The anti-hypertensive activity of simvastatin (10 mg/kg & 20 mg/kg) and reserpine (0.25mg/kg & 0.5 mg/kg) showed a significant dose dependent reduction in blood pressure and mean arterial pressure (P<0.0001) in Ang II induced hypertensive rats. Simvastatin (10 mg/kg and 20 mg/kg) and reserpine (0.25mg/kg & 0.5 mg/kg) treatment in diabetic rats significantly (P<0.0001) decreased blood glucose level in a dose dependent manner from day 1 to day 10 respectively when compared with diabetic control group. MS is a progressive and insidious disorder occurring in susceptible subgroups of population in response to adverse lifestyle and pathological conditions.